Abstract
The treatment and outcomes of diabetic macular oedema (DMO) have improved with the introduction of intravitreal injections. However, real-world data reveal that the burden of DMO treatment causes large gaps in outcomes between randomized clinical trials and daily clinical practice. Long-lasting intravitreal drugs and devices for DMO might reduce this disparity by achieving optimal treatment due to more feasible injection regimens. In this manuscript, we cover pharmacodynamics, preliminary results from clinical trials, and safety behavior about brolucizumab, faricimab, conbercept, KSI-301, and port-delivery system WR42221. These treatments might present the first step to control the global epidemic of diabetic eye disease in real life.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137–49.
Kempen JH, O’Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004;122:552–63.
Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556–64.
Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: Results from 2 phase iii randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789–801.
Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615–25. https://doi.org/10.1016/j.ophtha.2011.01.031.
Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399–405.
Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology. 2016;123:330–6.
Sivaprasad S, Oyetunde S. Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clin Ophthalmol. 2016;10:939–46.
Brook RA, Kleinman NL, Patel S, Smeeding JE, Beren IA, Turpcu A. United States comparative costs and absenteeism of diabetic ophthalmic conditions. Postgrad Med. 2015;127:455–62.
Egan C, Zhu H, Lee A, Sim D, Mitry D, Bailey C, et al. The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group, Report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema. Br J Ophthalmol. 2017;101:75–80.
Blinder KJ, Dugel PU, Chen S, Jumper JM, Walt JG, Hollander DA, et al. Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO study report 1). Clin Ophthalmol. 2017;11:393–401.
Boyer DS, Yoon YH, Belfort R, Bandello F, Maturi RK, Augustin AJ, et al. Trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121:1904–14.
Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119:2125–32.
Best A-L, Fajnkuchen F, Nghiem-Buffet S, Grenet T, Quentel G, Delahaye-Mazza C, et al. Treatment efficacy and compliance in patients with diabetic macular edema treated with ranibizumab in a real-life setting. J Ophthalmol. 2018;2018:4610129.
Weiss M, Sim DA, Herold T, Schumann RG, Liegl R, Kern C, et al. Compliance and adherence of patients with diabetic macular edema to intravitreal anti-vascular endothelial growth factor therapy in daily practice. Retina. 2018;38:2293–300.
Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72–84.
Agency EM. Assessment report; Beovu Assess Rep. EMA/23630/2020 Comm Med Prod Hum Use. 2019.
Nguyen QD, Das A, Do DV, Dugel PU, Gomes A, Holz FG, et al. Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration. Ophthalmology. 2020;127:963–76.
Holz FG, Dugel PU, Weissgerber G, Hamilton R, Silva R, Bandello F, et al. Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration. Ophthalmology. 2016;123:1080–9.
Novartis Pharmaceuticals. A study of the efficacy and safety of brolucizumab vs. aflibercept in patients with visual impairment due to diabetic macular edema (KITE). NCT03481660. 2018. https://clinicaltrials.gov/ct2/show/NCT03481660. Accessed 30 July 2021.
Novartis Pharmaceuticals. Study of efficacy and safety of brolucizumab vs. aflibercept in patients with visual impairment due to diabetic macular edema (KESTREL). NCT03481634. 2018. https://clinicaltrials.gov/ct2/show/NCT03481634. Accessed 30 July 2021.
Brown DM, Wolf S, Garweg J, Bandello F, Emanuelli A, Barranco JJE, et al. Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KITE and KESTREL studies. ARVO. 2021. https://arvo2021.arvo.org/meetings/virtual/qbuJrigF5i3qb97YW. Accessed 30 July 2021.
Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Faricimab: expanding horizon beyond VEGF. Eye (Lond). 2020;34:802–4.
Fuxe J, Tabruyn S, Colton K, Zaid H, Adams A, Baluk P, et al. Pericyte requirement for anti-leak action of angiopoietin-1 and vascular remodeling in sustained inflammation. Am J Pathol. 2011;178:2897–909.
Sahni J, Patel SS, Dugel PU, Khanani AM, Jhaveri CD, Wykoff CC, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology. 2019;126:1155–70.
File. R data on Roche’s faricimab meets primary endpoint and shows strong durability across two global phase III studies for diabetic macular edema, a leading cause of blindness. 2020. https://www.roche.com/media/releases/med-cor-2020-12-21.htm. Accessed 30 July 2021.
Roche H-L. A study to evaluate the efficacy and safety of faricimab (RO6867461) in participants with diabetic macular edema (YOSEMITE). NCT03622580. 2018. https://clinicaltrials.gov/ct2/show/NCT03622593. Accessed 30 July 2021.
Roche H-L. A study to evaluate the efficacy and safety of faricimab (RO6867461) in participants with diabetic macular edema (RHINE). NCT03622593. 2018. https://clinicaltrials.gov/ct2/show/NCT03622593. Accessed 30 July 2021.
Seah I, Zhao X, Lin Q, Liu Z, Su SZZ, Sen YuenY, et al. Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases. Eye (Lond). 2020;34:1341–56.
Campochiaro PA, Marcus DM, Awh CC, Regillo C, Adamis AP, Bantseev V, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial. Ophthalmology. 2019;126:1141–54.
ClinicalTrials.gov. This study will evaluate the efficacy, safety, and pharmacokinetics of the port delivery system with ranibizumab in participants with diabetic macular edema compared with intravitreal ranibizumab (Pagoda). 2019. https://clinicaltrials.gov/ct2/show/NCT04108156. Accessed 30 July 2021.
Liu K, Song Y, Xu G, Ye J, Wu Z, Liu X, et al. Conbercept for treatment of neovascular age-related macular degeneration: results of the randomized phase 3 PHOENIX study. Am J Ophthalmol. 2019;197:156–67.
ClinicalTrials.gov. Efficacy and safety trial of conbercept intravitreal injection for neovascular age-related macular degeneration (PANDA-2). 2018. https://clinicaltrials.gov/ct2/show/NCT03577899. Accessed 30 July 2021.
ClinicalTrials.gov. Efficacy and safety trial of conbercept intravitreal injection for neovascular age-related macular degeneration (PANDA-1). 2018. https://clinicaltrials.gov/ct2/show/NCT03577899. Accessed 30 July 2021.
Chengdu Kanghong Biotech Co. L. Safety and efficacy by multiple injection of KH902 in patients with diabetic macular edema (DME) (Frontier-1). 2011. https://clinicaltrials.gov/ct2/show/NCT03577899. Accessed 30 July 2021.
Chengdu Kanghong Biotech Co. L. Safety and efficacy study of conbercept in diabetic macular edema (DME) (Sailing). 2016. https://clinicaltrials.gov/ct2/show/study/NCT02194634. Accessed 30 July 2021.
Liu K, Wang H, He W, Ye J, Song Y, Wang Y, et al. Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. Br J Ophthalmol. 2021. bjophthalmol-2020-318690. http://bjo.bmj.com/content/early/2021/05/16/bjophthalmol-2020-318690.abstract.
CC W. Extended durability in exudative retinal diseases using the novel intravitreal anti-VEGF antibody biopolymer conjugate KSI-301: results from the Phase 1b study in patients with AMD, DME and RVO. San Francisco, CA: Academy of Ophthalmology Subspecialty Day Retina; 2019.
KS Inc. A study to evaluate the efficacy and safety of KSI-301, an anti-VEGF antibody biopolymer conjugate, versus aflibercept in patients with neovascular (wet) age-related macular degeneration (DAZZLE). 2019 https://clinicaltrials.gov/ct2/show/NCT04049266. Accessed 30 July 2021
KS Inc. A trial to evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with diabetic macular edema (DME) (GLEAM). 2020. https://clinicaltrials.gov/ct2/show/NCT04611152. Accessed 30 July 2021.
KS Inc. A study to evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with diabetic macular edema (DME) (GLIMMER). 2020. https://clinicaltrials.gov/ct2/show/NCT04603937. Accessed 30 July 2021.
KS Inc. Kodiak Sciences announces 1-year durability, efficacy and safety data from ongoing phase 1b study of KSI-301 in patients with wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion at the angiogenesis, exudation and degen. 2021. https://ir.kodiak.com/news-releases/news-release-details/kodiak-sciences-announces-1-year-durability-efficacy-and-safety. Accessed 30 July 2021.
Rosenfeld PJ, Browning DJ. Is this a 737 max moment for brolucizumab? Am J Ophthalmol. 2020;216:A7–A8.
Rajan K. Update: brolucizumab’s safety under review. Compr Ophthalmol Retin. 2019. https://clinicaltrials.gov/ct2/show/NCT04049266. Accessed 30 July 2021.
ASRS. American Society of Retina Specialists Research and Safety in Therapeutics Committee. 2019. https://www.asrs.org/about/committees/51. Accessed 30 July 2021.
Author information
Authors and Affiliations
Contributions
MI, DPG, AL, and DZ were responsible for screening potentially eligible studies, designing the review manuscript, and updating reference lists.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Iglicki, M., González, D.P., Loewenstein, A. et al. Next-generation anti-VEGF agents for diabetic macular oedema. Eye 36, 273–277 (2022). https://doi.org/10.1038/s41433-021-01722-8
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/s41433-021-01722-8
This article is cited by
-
“Real world outcomes of intravitreal brolucizumab for persistent diabetic macular edema”
International Journal of Retina and Vitreous (2025)
-
Efficacy and safety of dexamethasone versus intravitreal aflibercept implants for macular edema: a systematic review and meta-analysis
European Journal of Medical Research (2025)
-
Innovator ranibizumab ComparEd to Biosimilar ranibizumab in combination with Expansile gas in submaculaR HemorrhaGe: the ICEBERG study
BMC Ophthalmology (2025)
-
Diabetic foveal neovascularization is associated with diminished subfoveal choroidal flow on optical coherence tomography angiography
Eye (2025)
-
Natural remedies proposed for the management of diabetic retinopathy (DR): diabetic complications
Naunyn-Schmiedeberg's Archives of Pharmacology (2025)
